Skip to Content

ARS Pharmaceuticals

Securities Class Action

  • Date:
  • 10/5/2026
  • Company Name:
  • ARS Pharmaceuticals
  • Stock Symbol:
  • SPRY
  • Class Period:
  • FROM 3/9/2026 TO 6/24/2026
  • Status:
  • Filed
  • Filing Date:
  • 8/5/2026

Case Finder

Locate any case using the tools below.

Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against ARS Pharmaceuticals (“ARS” or the “Company”) (NYSE:SPRY) in the United States District Court for the Southern District of California on behalf of all persons and entities who purchased or otherwise acquired ARS securities between March 9, 2026, and June 24, 2026, both dates inclusive (the “Class Period”). Investors have until October 5, 2026 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
 
The complaint alleges defendants provided investors with material information concerning ARS's expected timeline for expanded insurance coverage for its epinephrine nasal spray, neffy, with CVS Caremark. Defendants' statements included, among other things, confidence that this coverage would begin on July 1, 2026, and be in place for the summer and back-to-school allergy seasons. Plaintiff contends that defendants provided these overwhelmingly positive statements to investors while, at the same time, failing to adequately disclose the risk that the expanded insurance coverage may not be available by the July 1 deadline, and thus, ARS would not have the expanded insurance coverage for neffy with CVS Caremark for the summer and back-to-school seasons.
 
If you purchased or otherwise acquired ARS shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Melissa Fortunato by email at investigations@bespc.com, telephone at (212) 355-4648, or by filling out the form below.  There is no cost or obligation to you.
Contact Instructions
Please contact Brandon Walker or Melissa Fortunato by email at investigations@bespc.com with any questions.
The individual or institution below (“Plaintiff”) has reviewed and agrees to the Bragar Eagel & Squire, P.C. (“BESPC”) retainer agreement and authorizes BESPC to prosecute an action on Plaintiff’s behalf under the federal securities laws or applicable state laws to recover damages on behalf of investors in ARS Pharmaceuticals. BESPC will prosecute the action on a full contingency basis and will forward all costs and expenses.
 

Case Finder

Locate any case using the tools below.

You may share a link to this page on any of the sites listed below or send link via email: